Bio-Rad Laboratories, Inc. (BIO)
| Market Cap | 10.13B +26.7% |
| Revenue (ttm) | 2.59B +1.4% |
| Net Income | 222.40M -30.3% |
| EPS | 8.26 -28.2% |
| Shares Out | 26.74M |
| PE Ratio | 45.89 |
| Forward PE | 36.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 107,694 |
| Open | 380.00 |
| Previous Close | 380.12 |
| Day's Range | 373.34 - 380.06 |
| 52-Week Range | 236.73 - 396.23 |
| Beta | 1.07 |
| Analysts | Hold |
| Price Target | 329.00 (-13.12%) |
| Earnings Date | Oct 29, 2026 |
About BIO
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory e... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for BIO stock is "Hold." The 12-month stock price target is $329.0, which is a decrease of -13.12% from the latest price.
News
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financia...
Bio-Rad Laboratories Earnings Call Transcript: Q2 2026
Q2 2026 revenue was flat year-over-year but up 10% sequentially, with clinical diagnostics returning to growth and digital PCR showing strong instrument sales. The company reaffirmed full-year guidance, announced a restructuring for long-term savings, and continues to face headwinds in China and academic markets.
Bio-Rad Laboratories Earnings release: Q2 2026
Bio-Rad Laboratories released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Bio-Rad Laboratories Quarterly report: Q2 2026
Bio-Rad Laboratories has published its Q2 2026 quarterly earnings report on August 4, 2026.
Bio-Rad Laboratories Slides: Q2 2026
Bio-Rad Laboratories has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Bio-Rad Reports Second-Quarter 2026 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...
BIO-key's Fireside Chat at Maxim Group Defense Tech Conf. to Webcast Thur.
Biometric authentication provider BIO-key's (BKYI) CEO will participate in a webcast fireside chat at Maxim Group's Defense Tech Conf. 6-25 at 4pm, track 2
Bio-Rad Laboratories Transcript: Jefferies Global Healthcare Conference 2026
Leadership is driving operational transformation, focusing on R&D productivity, targeted M&A, and regional growth. Digital PCR and Quality Controls are key growth drivers, while market softness and policy changes in the US, Europe, and China remain challenges.
Bio-Rad Laboratories Transcript: RBC Capital Markets Global Healthcare Conference 2026
Digital PCR instruments saw 24% growth, led by the QX700 series, and quality controls remain a global growth focus with attractive margins. Regional challenges in the Middle East and softness in early-stage biopharma are offset by stable China operations and new local manufacturing. Margin expansion and operational efficiencies are key near-term priorities.
Elliott builds big stake in life-science tools supplier Bio-Rad Labs, WSJ reports
Activist investor Elliott Investment Management has built a sizeable stake in U.S. diagnostics supplier Bio-Rad Laboratories , and plans to push the company to boost its underperforming stock price,...
Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad
Elliott also has a stake in German lab-equipment supplier Sartorius, where Bio-Rad is also an investor.
Bio-Rad to Participate in Upcoming Investor Conferences
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will p...
Bio-Rad Laboratories Earnings Call Transcript: Q1 2026
Q1 2026 revenue was within guidance despite a significant Middle East impact, with flat life science sales and modest diagnostics growth. Guidance was lowered for 2026, reflecting ongoing geopolitical and funding headwinds, but operational and innovation initiatives continue to drive long-term positioning.
Bio-Rad Laboratories Earnings release: Q1 2026
Bio-Rad Laboratories released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Bio-Rad Laboratories Quarterly report: Q1 2026
Bio-Rad Laboratories has published its Q1 2026 quarterly earnings report on April 30, 2026.
Bio-Rad Laboratories Slides: Q1 2026
Bio-Rad Laboratories has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Bio-Rad Reports First-Quarter 2026 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...
Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...
Bio-Rad Laboratories Proxy statement: Proxy filing
Bio-Rad Laboratories filed a proxy statement on March 25, 2026, providing details for shareholder voting and corporate governance matters.
Bio-Rad Laboratories Earnings Call Transcript: Q4 2025
Q4 and full year 2025 results met revised revenue and operating margin guidance, but gross margin lagged due to higher supply chain costs. Diagnostics returned to growth, ddPCR saw strong QX700 sales, and Process Chromatography faces near-term declines. 2026 guidance calls for modest revenue growth and margin improvement.
Bio-Rad Laboratories Annual report: Q4 2025
Bio-Rad Laboratories has published its Q4 2025 annual report on February 12, 2026.
Bio-Rad Laboratories Earnings release: Q4 2025
Bio-Rad Laboratories released its Q4 2025 earnings on February 12, 2026, summarizing the period's financial results.
Bio-Rad Laboratories Slides: Q4 2025
Bio-Rad Laboratories has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...